Registry update — unassessed
A PHASE II, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE ONGOING LUNG DECLINE WITH AGE INTENSIFIED RESPONSE (OLD AIR)
Trial registry update: RECRUITING. No results reported in the supplied registry record.
RCTN=40Routine significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Oct 15, 2026 · Discovered: Sep 15, 2026 · Assessed: — · Research update
What it does not prove
- The study results are not reported in the provided abstract, so no conclusions about fisetin's efficacy can be drawn
- A sample size of 40 as a Phase II pilot study provides limited statistical power to detect meaningful effects
- The short dosing strategy and specific participant selection (smokers and never-smokers) mean findings may not generalize to all older adults
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- 40
- Duration
- —
- Population
- Older adults aged 60 years and older, including individuals with a history of at least 10 pack-years of smoking as well as age-matched never-smokers
- Primary outcome
- Lung function and biomarkers of cellular senescence
- Effect size
- —
- Significance
- Not reported
- Journal
- Cedars-Sinai Medical Center
- Published
- Oct 15, 2026
Sources
Primary source
- Cedars-Sinai Medical Center ↗Clinical trial
Recorded source passages
Abstract or registry material supplied for assessment; source version 2. This is not a claim of full-text review.
This Phase II, randomized, double-blind, placebo-controlled pilot study will evaluate the effects of fisetin, a senolytic flavonoid compound, on lung function and biomarkers of cellular senescence in older adults aged 60 years and older.
Participants will include individuals with a history of at least 10 pack-years of smoking as well as age-matched never-smokers.
Forty participants will be randomized to receive either fisetin or placebo using a short-course "hit-and-run" dosing strategy (approximately 20 mg/kg/day orally for 2 consecutive days on Days 1-2 and Days 8-9).
Source versions
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.